Trial Profile
FOxTROT - Fluoropyrimidine, Oxaliplatin and Targeted Receptor Pre-Operative Therapy: a Controlled Trial in High-Risk Operable Colon Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- Acronyms FOxTROT
- 24 Oct 2023 Exploratory analysis results presented at the 48th European Society for Medical Oncology Congress.
- 16 Oct 2023 According to an Amgen media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology